Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Biorxiv : the Preprint Server for Biology
|
January 23, 2024
SORBET: Automated cell-neighborhood analysis of spatial transcriptomics or proteomics for interpretable sample classification via GNN
Shay Shimonov, Joseph M Cunningham, Ronen Talmon, et al.
Dermatologic Therapy
|
October 3, 2022
Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma
Rony Shreberk-Hassidim, Lilach Aizenbud, Shalev Lussheimer, et al.
Infection Control and Hospital Epidemiology
|
July 21, 2020
Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic
Dan M Kluger, Yariv Aizenbud, Ariel Jaffe, et al.
Frontiers in Oncology
|
March 30, 2022
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
Shlomit Jessel, Sarah A Weiss, Matthew Austin, et al.
Journal for Immunotherapy of Cancer
|
March 10, 2023
Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
Jasmine I Caulfield, Lilach Aizenbud, Ana Luisa Perdigoto, et al.
Journal for Immunotherapy of Cancer
|
August 16, 2023
ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis
Jacqueline E Mann, Liliana Lucca, Matthew R Austin, et al.
Nature
|
July 23, 2025
Humoral determinants of checkpoint immunotherapy
Yile Dai, Lilach Aizenbud, Kai Qin, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 17, 2023
IL-7R licenses a population of epigenetically poised memory CD8<sup>+</sup> T cells with superior antitumor efficacy that are critical for melanoma memory
Goran Micevic, Andrew Daniels, Karine Flem-Karlsen, et al.
Journal for Immunotherapy of Cancer
|
September 11, 2025
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes
Lilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, et al.
Research Square
|
March 11, 2024
Circulating Tumor Reactive KIR+CD8+ T cells Suppress Anti-Tumor Immunity in Patients with Melanoma
David Hafler, Benjamin Lu, Liliana Lucca, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Biorxiv : the Preprint Server for Biology
|
January 23, 2024
SORBET: Automated cell-neighborhood analysis of spatial transcriptomics or proteomics for interpretable sample classification via GNN
Shay Shimonov, Joseph M Cunningham, Ronen Talmon, et al.
Dermatologic Therapy
|
October 3, 2022
Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma
Rony Shreberk-Hassidim, Lilach Aizenbud, Shalev Lussheimer, et al.
Infection Control and Hospital Epidemiology
|
July 21, 2020
Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic
Dan M Kluger, Yariv Aizenbud, Ariel Jaffe, et al.
Frontiers in Oncology
|
March 30, 2022
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
Shlomit Jessel, Sarah A Weiss, Matthew Austin, et al.
Journal for Immunotherapy of Cancer
|
March 10, 2023
Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
Jasmine I Caulfield, Lilach Aizenbud, Ana Luisa Perdigoto, et al.
Journal for Immunotherapy of Cancer
|
August 16, 2023
ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis
Jacqueline E Mann, Liliana Lucca, Matthew R Austin, et al.
Nature
|
July 23, 2025
Humoral determinants of checkpoint immunotherapy
Yile Dai, Lilach Aizenbud, Kai Qin, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 17, 2023
IL-7R licenses a population of epigenetically poised memory CD8<sup>+</sup> T cells with superior antitumor efficacy that are critical for melanoma memory
Goran Micevic, Andrew Daniels, Karine Flem-Karlsen, et al.
Journal for Immunotherapy of Cancer
|
September 11, 2025
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes
Lilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, et al.
Research Square
|
March 11, 2024
Circulating Tumor Reactive KIR+CD8+ T cells Suppress Anti-Tumor Immunity in Patients with Melanoma
David Hafler, Benjamin Lu, Liliana Lucca, et al.
Page
of 2